{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Tharimmune, Inc."},"Symbol":{"label":"Symbol","value":"THAR"},"Address":{"label":"Address","value":"1200 ROUTE 22 EAST,SUITE 2000, BRIDGEWATER, New Jersey, 08807, United States"},"Phone":{"label":"Phone","value":"+1 908 955-3140"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug-resistant and devastating cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.hillstreambio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Randy D. Milby","title":"Chairman & Chief Executive Officer"},{"name":"Ron Weitzman","title":"Head-Clinical Development"},{"name":"Sireesh Appajosyula","title":"Chief Operating Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}